Canadian Agency for Drugs and Technologies in Health. (2017). Patient group input submissions AbobotulinumtoxinA (Dysport therapeutic ULS) for the symptomatic treatment of focal spasticity affection the upper limbs in adults. Canadian Agency for Drugs and Technologies in Health.
Cita Chicago Style (17a ed.)Canadian Agency for Drugs and Technologies in Health. Patient Group Input Submissions AbobotulinumtoxinA (Dysport Therapeutic ULS) for the Symptomatic Treatment of Focal Spasticity Affection the Upper Limbs in Adults. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2017.
Cita MLA (9a ed.)Canadian Agency for Drugs and Technologies in Health. Patient Group Input Submissions AbobotulinumtoxinA (Dysport Therapeutic ULS) for the Symptomatic Treatment of Focal Spasticity Affection the Upper Limbs in Adults. Canadian Agency for Drugs and Technologies in Health, 2017.
